1 mL BAC
5 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 1 mL
SingleInvestigationalMixedLow confidenceSourced
KPV
A short anti-inflammatory peptide with cell and animal evidence. A related oral analogue, K(D)PT, reached a small phase 2a colitis study but is not identical to injectable KPV.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
Two community-provenance subcutaneous lines from authenticated forum archives - a goal-based dose ladder and an expert frequency taper for the short half-life. Community reports only, not a validated or trial-verified schedule.
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.
Reported quantities by phase
Select a point for its calculation examples- Low start (titrate up)250 mcgReports begin near 250 mcg once daily and titrate by goal and response.
- Mild joint pain500 mcg+250 mcg
- Gut / GI inflammation1 mg+500 mcg
- Severe / chronic (up to 4 mg)2 mg+1 mgThe upper end of the goal ladder runs about 2-4 mg a day for severe or chronic inflammatory work.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 250 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw15 U
20-30 U reference band
2 mL BAC
10 units
resulting U-100 draw
- Concentration
- 2.5 mg/mL
- BAC added
- 2 mL
3 mL BAC
15 units
resulting U-100 draw
- Concentration
- 1.667 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human StudyOral related analogueTwice daily
Adults with mild-to-moderate ulcerative colitis
Related oral K(D)PT analogue studied at 20 mg, 50 mg or 100 mg twice daily
This eight-week phase 2a study evaluated a related oral molecule, not injectable KPV and not the listed research formulation.
View sourceCommunity GuideSubcutaneous in reportsOnce or twice daily
online research community reports
Subcutaneous reports range from 250-500 mcg daily to 2 mg morning plus 2 mg at night; blend reports often use 0.5-1 mg per component daily
An expert response says human data are absent and subcutaneous dosing is guesswork. These reports cannot be inferred from the oral K(D)PT study; raw/discussions/disc-ask-med-expert.md:8935-8938 and 9193-9222.
View sourceCommunity GuideSubcutaneous in reportsOnce to four times daily, tapering
authenticated research-forum (Peppys) KPV reports and expert guidance
Subcutaneous reports begin around 250 mcg once daily and titrate up on a goal-based ladder - roughly 250-500 mcg for mild joint pain, about 1 mg a day for gut inflammation and 2-4 mg a day for severe or chronic inflammation; an expert taper doses the same per-injection amount four then three then two times a day for the short half-life, and it is commonly stacked with GHK-Cu as KLOW
Forum provenance from an authenticated archive with usernames omitted, describing the KPV tripeptide and kept separate from the oral K(D)PT analogue in the phase 2a colitis trial. Reports span monotherapy and blends, cadence varies between continuous daily use and cycling, and the archive states human injectable data are absent.
View sourceEvidence summary
A short anti-inflammatory peptide with cell and animal evidence. A related oral analogue, K(D)PT, reached a small phase 2a colitis study but is not identical to injectable KPV.
Protocol basis
The page explicitly separates direct preclinical KPV research from a human trial of the related K(D)PT analogue. That distinction supports only low confidence.
Community provenance (Peppys)
An authenticated research-forum archive records subcutaneous use of the KPV tripeptide, kept distinct from the oral K(D)PT analogue studied in colitis. Reported quantities describe a goal-based ladder - roughly 250-500 mcg a day for mild joint pain, about 1 mg a day for gut inflammation and 2-4 mg a day for severe or chronic conditions - with most reports beginning near 250 mcg and titrating up. Because the peptide's half-life is described as about an hour, an expert report doses the same per-injection amount four, then three, then two times a day; KPV is very commonly stacked with GHK-Cu as "KLOW". Cadence ranges from continuous daily use to cycling, appetite increase is a disputed minority side effect, and usernames and post numbers are omitted. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.
What remains uncertain
A validated KPV formulation, human injectable pharmacokinetics and controlled clinical schedule have not been established.
Warnings and contraindications
K(D)PT clinical data cannot be treated as proof for KPV research vials.
The strongest direct KPV evidence is preclinical.
Oral and injectable exposure cannot be assumed equivalent.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.